DARE stock: buy or sell?

DARE stock price: $0.83 5.06% At close on August 22nd, 2019

Updated on:
August 22nd, 2019


Dare Bioscience ended today at $0.83 and skyrocketed a super good 5.06%.

Daré Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.

Should I buy DARE stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Dare Bioscience stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean DARE will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Dare Bioscience stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we detected 2 ratings published for DARE stock in the last 30 days.

Is DARE a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-4-4Maxim Groupn/aBuy

DARE stock analysis

Daily outlook

Shares of Dare Bioscience skyrocketed a super good 5.06% and closed at $0.83.

Dare Bioscience skyrocketed a super good 5.06% and closed at $0.83. Since price and SMA200d lines crossed down on May, DARE fell $-0.18 per share (-17.82%). DARE is retaking the upward trend marking a new rising bottom heading to break out over $0.99.

DARE stock chart (daily)

Weekly outlook

Dare Bioscience shares skyrocketed 7.79% this week, ending at $0.83. Early August DARE plummed a hair-raising -6.67% in just one week.

Since price and 40-weeks moving average lines crossed down early May, DARE fell $-0.15 per share (-15.31%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.

DARE stock chart (weekly)

DARE stock price history

DARE IPO was on April 10th, 2014 at $71.00 per share1. Since then, DARE stock lost a -98.80%, with a yearly average of -19.80%.

1: Adjusted price after possible price splits or reverse-splits.

DARE stock historical price chart

DARE stock reached 52-week highs on March at $3.25, and all-time highs 2015-03-19 with a price of 108.7.

DARE stock price target is $3.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Dare Bioscience stock was posted in the last month:
DARE stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-4-4Maxim GroupReiteratesn/a$3.00-
(in average)$0.00$3.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

Since last April, when Dare Bioscience posted its last earnings report, it . As soon as we get its actual EPS from the earnings report, we will extend this report.
DARE earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2016, Dare Bioscience annual turnover climbed an outstanding 857.50% to $0.77 M dollars from $0.08 marked in 2014. When comparing 2016 vs 2014, likewise, profit margin (that is, the net income divided by revenues) rocketed a 24,046.30% to -5,131.20%.

DARE annual Sales and Income evolution
2013$6.00 M-$0.00 M0.0%-
2014$0.08 M-98.67%$-23.34 M-29177.5%0.00%
2016$0.77 M857.50%$-39.31 M-5131.2%68.39%

Quarterly financial results

Reported quarter income marked $-2.92 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Dare Bioscience sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, Dare Bioscience posted 7 positive quarters in a row.
DARE quarterly Sales and Income evolution
2017-Q1$1,192.00 M-$0.00 M0.0%-
2017-Q2$642.00 M-46.14%$0.00 M0.0%0.00%

Dare Bioscience ownership

When you are planning to buy a stock, it's always worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Dare Bioscience, 16.92% of all outstanding shares are owned by its staff.

In case of Dare Bioscience stock, 8.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for DARE stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

Market cap$0.0 M$67.1 B$312.2 M$387.3 M$1.3 B
Total shares0.0 M701.0 M53.0 M149.5 M14.3 M
Float shares13.9 M706.3 M40.5 M135.2 M6.4 M
  - Institutional holdings (%)8.1%77.6%103.6%84.5%97.1%
  - Insider holdings (%)16.9%0.2%3.0%1.6%11.3%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DARE summary

Thursday, August 22nd, 2019
Day range$0.75 - $0.94
Previous close$0.79
Session gain5.06%
Average true range$0.07
50d mov avg$0.80
100d mov avg$0.91
200d mov avg$0.91
Daily patternlb02a
Weekly pattern lt03a

Dare Bioscience performance

To better understand Dare Bioscience performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Dare Bioscience performance to Celgene, Clovis Oncology, ImmunoGen, Madrigal Pharmaceuticals, Nektar, Seattle Genetics and Spectrum Pharmaceuticals:
DAREDare Bioscience-4.60%-2.35%-19.42%
CLVSClovis Oncology-64.81%-76.74%-83.24%
MDGLMadrigal Pharmace...-4.74%-25.99%-61.51%
SGENSeattle Genetics13.34%10.01%5.05%
SPPISpectrum Pharmace...2.27%-31.19%-66.90%

Dare Bioscience competitors

One check before investing in any stock is to review a list of its competitors, in this case for Dare Bioscience. We chose 7 companies as Dare Bioscience competitors as they are in the same industry or have similar market objectives.